Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions

amphotericin B

  • Azole and Amphotericin B MIC Values against <em>Aspergillus fumigatus</em>: High Agreement between Spectrophotometric and Visual Readings Using the EUCAST EDef 9.3.2 Procedure
    Susceptibility
    Azole and Amphotericin B MIC Values against Aspergillus fumigatus: High Agreement between Spectrophotometric and Visual Readings Using the EUCAST EDef 9.3.2 Procedure

    The EUCAST EDef 9.3.2 procedure recommends visual readings of azole and amphotericin B MICs against Aspergillus spp. Visual determination of MICs may be challenging. In this work, we aim to obtain and compare visual and spectrophotometric MIC readings of azoles and amphotericin B against Aspergillus fumigatus sensu lato isolates. A total of 847...

    Julia Serrano-Lobo, Ana Gómez, Waldo Sánchez-Yebra, Miguel Fajardo, Belén Lorenzo, Ferrán Sánchez-Reus, Inmaculada Vidal, Marina Fernández-Torres, Isabel Sánchez-Romero, Carlos Ruiz de Alegría-Puig, José Luis del Pozo, Patricia Muñoz, Pilar Escribano, Jesús Guinea
    and on behalf of the ASPEIN Study Group
  • Assessing the Safety, Tolerability, Pharmacokinetics, and Biodistribution of Novel Oral Formulations of Amphotericin B following Single- and Multiple-Dose Administration to Beagle Dogs
    Experimental Therapeutics
    Assessing the Safety, Tolerability, Pharmacokinetics, and Biodistribution of Novel Oral Formulations of Amphotericin B following Single- and Multiple-Dose Administration to Beagle Dogs

    The purpose of this study was to assess the safety, tolerability, pharmacokinetics (PK), and biodistribution of novel oral amphotericin B (AmpB) formulations following single- and multiple-oral-dose administration to healthy beagle dogs. The liquid formulation of AmpB was administered to three male dogs, and the capsule formulations of AmpB were administered to each of two groups of six male dogs. Blood was collected for pharmacokinetic...

    Kishor M. Wasan, Ellen K. Wasan, Peter Hnik
  • Amphotericin B Inhibits <span class="named-content genus-species" id="named-content-1">Mycobacterium tuberculosis</span> Infection of Human Alveolar Type II Epithelial A549 Cells
    Letter to the Editor
    Amphotericin B Inhibits Mycobacterium tuberculosis Infection of Human Alveolar Type II Epithelial A549 Cells
    Sabrina Mariotti, Raffaela Teloni, Valeria de Turris, Manuela Pardini, Daniela Peruzzu, Katia Fecchi, Roberto Nisini, Maria Cristina Gagliardi
  • Open Access
    Phase I EnACT Trial of the Safety and Tolerability of a Novel Oral Formulation of Amphotericin B
    Clinical Therapeutics
    Phase I EnACT Trial of the Safety and Tolerability of a Novel Oral Formulation of Amphotericin B

    Amphotericin B deoxycholate (AMB) has substantial toxicities. A novel encochleated amphotericin B deoxycholate (cAMB) formulation has oral bioavailability, efficacy in an animal model, and minimal toxicity due to targeted drug delivery into macrophages, where intracellular fungi reside. We conducted a phase I, ascending-dose trial of cAMB administered at 1.0 g, 1.5 g, or 2.0 g per day in 4 to 6 divided doses among HIV-positive survivors...

    Caleb P. Skipper, Mucunguzi Atukunda, Anna Stadelman, Nicole W. Engen, Ananta S. Bangdiwala, Katherine H. Hullsiek, Mahsa Abassi, Joshua Rhein, Melanie R. Nicol, Eva Laker, Darlisha A. Williams, Raphael Mannino, Theresa Matkovits, David B. Meya, David R. Boulware
  • Manogepix (APX001A) <em>In Vitro</em> Activity against <span class="named-content genus-species" id="named-content-1">Candida auris</span>: Head-to-Head Comparison of EUCAST and CLSI MICs
    Susceptibility
    Manogepix (APX001A) In Vitro Activity against Candida auris: Head-to-Head Comparison of EUCAST and CLSI MICs

    Fosmanogepix is a novel prodrug in a new class of antifungal agents. Manogepix is the active moiety. We evaluated the CLSI and EUCAST MICs of manogepix and eight comparators against Candida auris. CLSI M27-A3 susceptibility testing of manogepix was performed for 122 C. auris isolates and compared to...

    Maiken Cavling Arendrup, Anuradha Chowdhary, Karin Meinike Jørgensen, Joseph Meletiadis
  • Species Distribution and Comparison between EUCAST and Gradient Concentration Strips Methods for Antifungal Susceptibility Testing of 112 <em>Aspergillus</em> Section <em>Nigri</em> Isolates
    Susceptibility
    Species Distribution and Comparison between EUCAST and Gradient Concentration Strips Methods for Antifungal Susceptibility Testing of 112 Aspergillus Section Nigri Isolates

    Aspergillus niger, the third species responsible for invasive aspergillosis, has been considered as a homogeneous species until DNA-based identification uncovered many cryptic species. These species have been recently reclassified into the Aspergillus section Nigri. However, little is yet known among the section Nigri about the species...

    B. Carrara, R. Richards, S. Imbert, F. Morio, M. Sasso, N. Zahr, A. C. Normand, P. Le Pape, L. Lachaud, S. Ranque, D. Maubon, R. Piarroux, A. Fekkar
  • Open Access
    Lactoferrin Is Broadly Active against Yeasts and Highly Synergistic with Amphotericin B
    Susceptibility
    Lactoferrin Is Broadly Active against Yeasts and Highly Synergistic with Amphotericin B

    Lactoferrin (LF) is a multifunctional milk protein with antimicrobial activity against a range of pathogens. While numerous studies report that LF is active against fungi, there are considerable differences in the level of antifungal activity and the capacity of LF to interact with other drugs. Here we undertook a comprehensive evaluation of the antifungal spectrum of activity of three defined sources of LF across 22 yeast and 24 mold...

    Kenya E. Fernandes, Kerry Weeks, Dee A. Carter
  • Identification of Off-Patent Drugs That Show Synergism with Amphotericin B or That Present Antifungal Action against <span class="named-content genus-species" id="named-content-1">Cryptococcus neoformans</span> and <em>Candida</em> spp.
    Experimental Therapeutics
    Identification of Off-Patent Drugs That Show Synergism with Amphotericin B or That Present Antifungal Action against Cryptococcus neoformans and Candida spp.

    Amphotericin B (AmB) is the antifungal with the strongest fungicidal activity, but its use has several limitations, mainly associated with its toxicity. Although some lipidic and liposomal formulations that present reduced toxicity are available, their price limits their application in developing countries. Flucytosine (5FC) has shown synergistic effect with AmB for treatment of some fungal infections, such as cryptococcosis, but again...

    Suélen Andreia Rossi, Haroldo Cesar de Oliveira, Daniel Agreda-Mellon, José Lucio, Maria José Soares Mendes-Giannini, Jesús Pablo García-Cambero, Oscar Zaragoza
  • Amphotericin B Penetrates into the Central Nervous System through Focal Disruption of the Blood-Brain Barrier in Experimental Hematogenous <em>Candida</em> Meningoencephalitis
    Experimental Therapeutics
    Amphotericin B Penetrates into the Central Nervous System through Focal Disruption of the Blood-Brain Barrier in Experimental Hematogenous Candida Meningoencephalitis

    Hematogenous Candida meningoencephalitis (HCME) is a life-threatening complication of neonates and immunocompromised children. Amphotericin B (AmB) shows poor permeation and low cerebrospinal fluid (CSF) concentrations but is effective in the treatment of HCME. In order to better understand the mechanism of CNS penetration of AmB, we hypothesized that AmB may achieve focally higher concentrations in infected CNS lesions.

    ...
    Vidmantas Petraitis, Ruta Petraitiene, Jessica M. Valdez, Vasilios Pyrgos, Martin J. Lizak, Brenda A. Klaunberg, Darius Kalasauskas, Algidas Basevicius, John D. Bacher, Daniel K. Benjamin, William W. Hope, Thomas J. Walsh
  • <em>In Vitro</em> Antifungal Combination of Flucytosine with Amphotericin B, Voriconazole, or Micafungin against <span class="named-content genus-species" id="named-content-1">Candida auris</span> Shows No Antagonism
    Susceptibility
    In Vitro Antifungal Combination of Flucytosine with Amphotericin B, Voriconazole, or Micafungin against Candida auris Shows No Antagonism

    Candida auris is an emerging, multidrug-resistant pathogen responsible for invasive hospital-acquired infections. Flucytosine is an effective anti-Candida species drug, but which cannot be used as a monotherapy because of the risk of development of resistant mutants during treatment. It is, therefore, noteworthy to test possible combinations with flucytosine...

    A. L. Bidaud, F. Botterel, A. Chowdhary, E. Dannaoui

Pages

  • Next
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 29
Back to top

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596